AAAAAA

   
Results: 1-19 |
Results: 19
NOVELTIES IN THE FIELD OF ANTI-INFECTIVES IN 1997
Authors: BRYSKIER A
Citation: A. Bryskier, NOVELTIES IN THE FIELD OF ANTI-INFECTIVES IN 1997, Clinical infectious diseases, 27(4), 1998, pp. 865-883
INTERACTIONS BETWEEN HMR-3647, A NEW KETOLIDE, AND HUMAN POLYMORPHONUCLEAR NEUTROPHILS
Authors: VAZIFEH D PREIRA A BRYSKIER A LABRO MT
Citation: D. Vazifeh et al., INTERACTIONS BETWEEN HMR-3647, A NEW KETOLIDE, AND HUMAN POLYMORPHONUCLEAR NEUTROPHILS, Antimicrobial agents and chemotherapy, 42(8), 1998, pp. 1944-1951
IN-VITRO ACTIVITIES OF THE NEW KETOLIDE ANTIBIOTICS HMR-3004 AND HMR-3647 AGAINST STREPTOCOCCUS-PNEUMONIAE IN GERMANY
Authors: REINERT RR BRYSKIER A LUTTICKEN R
Citation: Rr. Reinert et al., IN-VITRO ACTIVITIES OF THE NEW KETOLIDE ANTIBIOTICS HMR-3004 AND HMR-3647 AGAINST STREPTOCOCCUS-PNEUMONIAE IN GERMANY, Antimicrobial agents and chemotherapy, 42(6), 1998, pp. 1509-1511
IN-VITRO SUSCEPTIBILITIES OF BORDETELLA-PERTUSSIS AND BORDETELLA-PARAPERTUSSIS TO 2 KETOLIDES (HMR-3004 AND HMR-3647), 4 MACROLIDES (AZITBROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN-A, AND ROXITHROMYCIN), AND 2 ANSAMYCINS (RIFAMPIN AND RIFAPENTINE)
Authors: HOPPE JE BRYSKIER A
Citation: Je. Hoppe et A. Bryskier, IN-VITRO SUSCEPTIBILITIES OF BORDETELLA-PERTUSSIS AND BORDETELLA-PARAPERTUSSIS TO 2 KETOLIDES (HMR-3004 AND HMR-3647), 4 MACROLIDES (AZITBROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN-A, AND ROXITHROMYCIN), AND 2 ANSAMYCINS (RIFAMPIN AND RIFAPENTINE), Antimicrobial agents and chemotherapy, 42(4), 1998, pp. 965-966
MACROLIDES - RENEWED INTEREST AND PERSPEC TIVES
Authors: BRYSKIER A
Citation: A. Bryskier, MACROLIDES - RENEWED INTEREST AND PERSPEC TIVES, La Presse medicale, 26(22), 1997, pp. 1063-1069
BACTERICIDAL ACTIVITY OF CEFODIZIME ON ENTEROBACTERIACEAE IN AN IN-VITRO MODEL SIMULATING PLASMA PHARMACOKINETICS IN HUMANS
Authors: PECHINOT A NEUWIRTH C BRYSKIER A DUEZ JM KAZMIERCZAK A
Citation: A. Pechinot et al., BACTERICIDAL ACTIVITY OF CEFODIZIME ON ENTEROBACTERIACEAE IN AN IN-VITRO MODEL SIMULATING PLASMA PHARMACOKINETICS IN HUMANS, Journal of antimicrobial chemotherapy, 39(2), 1997, pp. 157-162
THE KETOLIDE ANTIBIOTICS HMR-3647 AND HMR-3004 ARE ACTIVE AGAINST TOXOPLASMA-GONDII IN-VITRO AND IN MURINE MODELS OF INFECTION
Authors: ARAUJO FG KHAN AA SLIFER TL BRYSKIER A REMINGTON JS
Citation: Fg. Araujo et al., THE KETOLIDE ANTIBIOTICS HMR-3647 AND HMR-3004 ARE ACTIVE AGAINST TOXOPLASMA-GONDII IN-VITRO AND IN MURINE MODELS OF INFECTION, Antimicrobial agents and chemotherapy, 41(10), 1997, pp. 2137-2140
IN-VITRO ACTIVITIES OF LEVOFLOXACIN USED ALONE AND IN COMBINATION WITH FIRST-LINE AND 2ND-LINE ANTITUBERCULOUS DRUGS AGAINST MYCOBACTERIUM-TUBERCULOSIS
Authors: RASTOGI N GOH KS BRYSKIER A DEVALLOIS A
Citation: N. Rastogi et al., IN-VITRO ACTIVITIES OF LEVOFLOXACIN USED ALONE AND IN COMBINATION WITH FIRST-LINE AND 2ND-LINE ANTITUBERCULOUS DRUGS AGAINST MYCOBACTERIUM-TUBERCULOSIS, Antimicrobial agents and chemotherapy, 40(7), 1996, pp. 1610-1616
IN-VITRO SUSCEPTIBILITY OF PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE TO LEVOFLOXACIN, SELECTION OF RESISTANT MUTANTS, AND TIME-KILL SYNERGY STUDIES OF LEVOFLOXACIN COMBINED WITH VANCOMYCIN, TEICOPLANIN, FUSIDIC ACID, AND RIFAMPIN
Authors: KLUGMAN KP CAPPER T BRYSKIER A
Citation: Kp. Klugman et al., IN-VITRO SUSCEPTIBILITY OF PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE TO LEVOFLOXACIN, SELECTION OF RESISTANT MUTANTS, AND TIME-KILL SYNERGY STUDIES OF LEVOFLOXACIN COMBINED WITH VANCOMYCIN, TEICOPLANIN, FUSIDIC ACID, AND RIFAMPIN, Antimicrobial agents and chemotherapy, 40(12), 1996, pp. 2802-2804
SPECTRUM OF ACTIVITY OF LEVOFLOXACIN AGAINST NONTUBERCULOUS MYCOBACTERIA AND ITS ACTIVITY AGAINST THE MYCOBACTERIUM-AVIUM COMPLEX IN COMBINATION WITH ETHAMBUTOL, RIFAMPIN, ROXITHROMYCIN, AMIKACIN, AND CLOFAZIMINE
Authors: RASTOGI N GOH KS BRYSKIER A DEVALLOIS A
Citation: N. Rastogi et al., SPECTRUM OF ACTIVITY OF LEVOFLOXACIN AGAINST NONTUBERCULOUS MYCOBACTERIA AND ITS ACTIVITY AGAINST THE MYCOBACTERIUM-AVIUM COMPLEX IN COMBINATION WITH ETHAMBUTOL, RIFAMPIN, ROXITHROMYCIN, AMIKACIN, AND CLOFAZIMINE, Antimicrobial agents and chemotherapy, 40(11), 1996, pp. 2483-2487
IN-VITRO ACTIVITIES OF 14 ANTIBIOTICS AGAINST 100 HUMAN ISOLATES OF YERSINIA-PESTIS FROM A SOUTHERN AFRICAN PLAGUE FOCUS
Authors: FREAN JA ARNTZEN L CAPPER T BRYSKIER A KLUGMAN KP
Citation: Ja. Frean et al., IN-VITRO ACTIVITIES OF 14 ANTIBIOTICS AGAINST 100 HUMAN ISOLATES OF YERSINIA-PESTIS FROM A SOUTHERN AFRICAN PLAGUE FOCUS, Antimicrobial agents and chemotherapy, 40(11), 1996, pp. 2646-2647
ANTIBIOTIC-THERAPY - PAST, PRESENT AND FU TURE
Authors: BRYSKIER A
Citation: A. Bryskier, ANTIBIOTIC-THERAPY - PAST, PRESENT AND FU TURE, La Presse medicale, 24(2), 1995, pp. 55
IN-VITRO AND IN-VIVO ACTIVITIES OF ROXITHROMYCIN IN COMBINATION WITH PYRIMETHAMINE OR SULFADIAZINE AGAINST TOXOPLASMA-GONDII
Authors: ROMAND S BRYSKIER A MOUTOT M DEROUIN F
Citation: S. Romand et al., IN-VITRO AND IN-VIVO ACTIVITIES OF ROXITHROMYCIN IN COMBINATION WITH PYRIMETHAMINE OR SULFADIAZINE AGAINST TOXOPLASMA-GONDII, Journal of antimicrobial chemotherapy, 35(6), 1995, pp. 821-832
PHARMACOKINETICS OF CEFODIZIME FOLLOWING SINGLE DOSES OF 0.5, 1.0, 2.0, AND 3.0 GRAMS ADMINISTERED INTRAVENOUSLY TO HEALTHY-VOLUNTEERS
Authors: LENFANT B NAMOUR F LOGEAIS C COUSSEDIERE D RIVAULT O BRYSKIER A SURJUS A
Citation: B. Lenfant et al., PHARMACOKINETICS OF CEFODIZIME FOLLOWING SINGLE DOSES OF 0.5, 1.0, 2.0, AND 3.0 GRAMS ADMINISTERED INTRAVENOUSLY TO HEALTHY-VOLUNTEERS, Antimicrobial agents and chemotherapy, 39(9), 1995, pp. 2037-2041
INTRACELLULAR ACTIVITIES OF ROXITHROMYCIN USED ALONE AND IN ASSOCIATION WITH OTHER DRUGS AGAINST MYCOBACTERIUM-AVIUM COMPLEX IN HUMAN MACROPHAGES
Authors: RASTOGI N LABROUSSE V BRYSKIER A
Citation: N. Rastogi et al., INTRACELLULAR ACTIVITIES OF ROXITHROMYCIN USED ALONE AND IN ASSOCIATION WITH OTHER DRUGS AGAINST MYCOBACTERIUM-AVIUM COMPLEX IN HUMAN MACROPHAGES, Antimicrobial agents and chemotherapy, 39(4), 1995, pp. 976-978
MACROLIDES - NEW THERAPEUTIC PRESPECTIVES
Authors: BRYSKIER A LABRO MT
Citation: A. Bryskier et Mt. Labro, MACROLIDES - NEW THERAPEUTIC PRESPECTIVES, La Presse medicale, 23(38), 1994, pp. 1762-1766
ACTIVITIES OF ROXITHROMYCIN USED ALONE AND IN COMBINATION WITH ETHAMBUTOL, RIFAMPIN, AMIKACIN, OFLOXACIN, AND CLOFAZIMINE AGAINST MYCOBACTERIUM-AVIUM COMPLEX
Authors: RASTOGI N GOH KS BRYSKIER A
Citation: N. Rastogi et al., ACTIVITIES OF ROXITHROMYCIN USED ALONE AND IN COMBINATION WITH ETHAMBUTOL, RIFAMPIN, AMIKACIN, OFLOXACIN, AND CLOFAZIMINE AGAINST MYCOBACTERIUM-AVIUM COMPLEX, Antimicrobial agents and chemotherapy, 38(6), 1994, pp. 1433-1438
IN-VITRO ACTIVITY OF ROXITHROMYCIN AGAINST 16 SPECIES OF ATYPICAL MYCOBACTERIA AND EFFECT OF PH ON ITS RADIOMETRIC MICS
Authors: RASTOGI N GOH KS BRYSKIER A
Citation: N. Rastogi et al., IN-VITRO ACTIVITY OF ROXITHROMYCIN AGAINST 16 SPECIES OF ATYPICAL MYCOBACTERIA AND EFFECT OF PH ON ITS RADIOMETRIC MICS, Antimicrobial agents and chemotherapy, 37(7), 1993, pp. 1560-1562
PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AMODIAQUINE AND ITS 2 METABOLITES AFTER A SINGLE ORAL DOSE IN HUMAN VOLUNTEERS
Authors: LAURENT F SAIVIN S CHRETIEN P MAGNAVAL JF PEYRON F SQALLI A TUFENKJI AE COULAIS Y BABA H CAMPISTRON G REGIS H AMBROISETHOMAS P BRYSKIER A HOUIN G
Citation: F. Laurent et al., PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AMODIAQUINE AND ITS 2 METABOLITES AFTER A SINGLE ORAL DOSE IN HUMAN VOLUNTEERS, Arzneimittel-Forschung, 43-1(5), 1993, pp. 612-616
Risultati: 1-19 |